Beneficial effects of quercetin in COPD - a preliminary clinical trial

槲皮素对慢性阻塞性肺病的有益作用——初步临床试验

• 批准号: 8355108
• 负责人: Fernando J Martinez
• 金额: $ 19.44万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-30 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8355108
• 关键词: 3-nitrotyrosine; Adrenal Cortex Hormones; Adverse effects; Agonist; Anti-Inflammatory Agents; Anti-inflammatory; Antioxidants; Apple; Asthma; Biological; Biological Availability; Biological Factors; Biological Markers; Breathing; Bronchial Hyperreactivity; Bronchodilator Agents; C-reactive protein; CCL18 gene; CD40 Ligand; Cause of Death; Chemicals; Chronic Obstructive Airway Disease; Chronic lung disease; Clara cell-specific protein; Clinical; Clinical Trials; Comorbidity; Data; Diet; Dietary Flavonoid; Disease; Dose; Drug Formulations; Epidemiologic Studies; Flavonoids; Food; Free Radicals; Frequencies; Future; Goals; High Pressure Liquid Chromatography; In Vitro; Inflammation; Inflammatory; Influenza; Intake; Intercellular adhesion molecule 1; Interleukin-6; Lung Inflammation; Lung diseases; Malondialdehyde; Measures; Monitor; Mus; Onions; Oral; Outcome; Oxidants; Oxidative Stress; Patients; Pharmaceutical Preparations; Physical Examination; Pilot Projects; Placebos; Plants; Plasma; Pneumonia; Procedures; Property; Proteins; Publishing; Pulmonary Sarcoidosis; Pulmonary Surfactant-Associated Protein D; Quercetin; Questionnaires; Reduced Glutathione; Research Personnel; Rhinovirus; Risk; Running; Safety; Serum; Severities; Smoking History; Spirometry; Sputum; Structure of parenchyma of lung; Supplementation; Symptoms; Testing; Therapeutic; Treatment Protocols; cytokine; dosage; fruits and vegetables; improved; in vivo; inflammatory marker; phenoxy radical; prevent; pulmonary function; response; volunteer

DESCRIPTION (provided by applicant): Quercetin, a plant flavonoid widely found in fruits and vegetables, is a potent antioxidant and anti- inflammatory. We recently showed that daily oral treatment with low levels of quercetin decreases oxidative stress, inflammation and prevents progression of lung disease in mice which display typical features of chronic obstructive lung disease (COPD) Our pilot studies also suggest that quercetin inhibits replication of rhinovirus, a major cause of COPD exacerbations. Finally, large epidemiological studies have suggested that a high- quercetin diet decreases the risk of COPD. Together, these data suggest that quercetin would be beneficial in the treatment of COPD. Nevertheless, key methodologic issues have not been resolved, including the dosage and frequency of supplementation, bioavailability, safety, dose-response relationship, or the appropriate biomarkers which reflect clinical outcomes in this disease. The overall goal of this application is to obtain the information necessary for large clinical trials in COPD. To accomplish this goal, we propose the following Specific Aims. 1. Determine if once-daily doses of quercetin are safe, acceptable and reach therapeutic concentrations in the plasma of patients with COPD. Using a quercetin formulation that has been "generally recognized as safe" by the FDA (Quercegen Pharma, Sudbury, MA), we will test the hypotheses that: 1) dietary flavonoid intake can be accurately monitored by questionnaire; and 2) daily supplementation of quercetin increases plasma quercetin levels in COPD patients; and 3) quercetin can be administered to patients with COPD of varying severity without adverse side effects. 2. Determine the effect of quercetin on oxidative stress, lung inflammation and pulmonary function in patients with COPD. We hypothesize that: 1) oxidative and inflammatory biomarkers can be safely and accurately measured in the serum and sputum of patients with COPD; 2) daily treatment with quercetin will reduce plasma and sputum markers of oxidative stress and inflammation; 3) daily treatment with quercetin will improve pulmonary function in patients with COPD. Results from these studies will provide data on the quercetin dosage and biological endpoints needed to carry out large clinical trials examining the efficacy of quercetin in COPD. PUBLIC HEALTH RELEVANCE: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the U.S. Current treatment regimens for COPD are only partially effective, expensive, and often not adhered to by patients. In contrast to standard medications, natural products may have fewer side effects and be easy and inexpensive to use. Quercetin, a dietary chemical found in foods such as apples and onions is a natural product with anti- oxidant and anti-inflammatory properties. Our preliminary data and published studies suggest that quercetin may be useful in the treatment of COPD. The goal of this proposal is to perform a pilot study of quercetin in patients with COPD. The information gained from this study, including the correct dosage of medication and safety profile, will enable researchers to plan a large clinical trial of quercetin in the future.

描述（由申请人提供）：槲皮素是一种广泛存在于水果和蔬菜中的植物类黄酮，是一种有效的抗氧化剂和抗炎剂。我们最近表明，每天口服低水平的槲皮素可以减少小鼠的氧化应激和炎症，并防止小鼠肺部疾病的进展，这些小鼠表现出慢性阻塞性肺病（COPD）的典型特征。我们的初步研究还表明，槲皮素可以抑制鼻病毒的复制，鼻病毒是一种鼻病毒。 COPD 恶化的主要原因。最后，大型流行病学研究表明，高槲皮素饮食可降低慢性阻塞性肺病的风险。总之，这些数据表明槲皮素有益于慢性阻塞性肺病的治疗。然而，关键的方法学问题尚未解决，包括补充的剂量和频率、生物利用度、安全性、剂量反应关系或反映该疾病临床结果的适当生物标志物。该应用程序的总体目标是获取 COPD 大型临床试验所需的信息。为了实现这一目标，我们提出以下具体目标。 1. 确定每日一次剂量的槲皮素是否安全、可接受并达到 COPD 患者血浆中的治疗浓度。使用 FDA（Quercegen Pharma，萨德伯里，马萨诸塞州）“普遍认为安全”的槲皮素配方，我们将测试以下假设：1）可以通过问卷调查准确监测膳食类黄酮摄入量； 2) 每日补充槲皮素可增加慢性阻塞性肺病患者的血浆槲皮素水平； 3) 槲皮素可用于不同严重程度的慢性阻塞性肺病患者，且不会产生不良副作用。 2.确定槲皮素对COPD患者氧化应激、肺部炎症和肺功能的影响。我们假设：1）可以安全、准确地测量 COPD 患者血清和痰液中的氧化和炎症生物标志物； 2）每日使用槲皮素治疗会降低血浆和痰液中氧化应激和炎症的标志物； 3）每日使用槲皮素治疗可改善COPD患者的肺功能。这些研究的结果将提供槲皮素剂量和生物学终点的数据，以进行大型临床试验来检查槲皮素对慢性阻塞性肺病的疗效。 公众健康相关性：慢性阻塞性肺病 (COPD) 是美国第三大死亡原因。目前的 COPD 治疗方案仅部分有效，价格昂贵，而且患者往往不坚持治疗。与标准药物相比，天然产品可能具有较少的副作用，并且使用起来简单且便宜。槲皮素是一种存在于苹果和洋葱等食物中的膳食化学物质，是一种具有抗氧化和抗炎特性的天然产品。我们的初步数据和已发表的研究表明槲皮素可能有助于治疗慢性阻塞性肺病。该提案的目标是对慢性阻塞性肺病患者进行槲皮素的初步研究。从这项研究中获得的信息，包括正确的药物剂量和安全性概况，将使研究人员能够计划未来对槲皮素进行大型临床试验。